Merck now holds 22 CRISPR-related patents worldwide across nine different geographies.

- Patents cover Paired Cas9 Nickase CRISPR genome-editing technology to advance gene therapy and research.

DARMSTADT, Germany, Nov. 26, 2019 /PRNewswire/ — Merck, a leading science and technology company, today announced that the Japan Patent Office and the Intellectual Property Office of Singapore have each allowed the company’s patent application for the use of paired CRISPR nickases, bringing Merck’s number of patents to 22 worldwide.